Swiss AI start-up Atlas Bio raises $12.5 million in round led by Creandum

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

Atlas Bio, a Swiss AI start-up, has raised $12.5 million (€11.2 million) led by Swedish firm Creandum, an early Spotify and Trade Republic backer.

The plan is merely to replace phase II trials, which it says cost over $100 million, last two to three years and see about 70% of drugs fail, with 12-week simulations. First trial results are due within six weeks.